Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Robert Cohen who wrote (15815)	2/24/1998 9:37:00 PM
From: Pseudo Biologist	Read Replies (1) \| Respond to of 32384

Robert, Your memory serves you right. Here is the abstract (I believe Henry provided an indirect link to same a few posts back): Cancer Res 1996 Dec 15;56(24):5566-5570 Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Gottardis MM, Bischoff ED, Shirley MA, Wagoner MA, Lamph WW, Heyman RA Department of Endocrine Research, Ligand Pharmaceuticals, Inc., San Diego, California 92121, USA. Recently, 9-cis retinoic acid, a high affinity ligand for retinoic acid receptors and retinoid X-receptors (RXRs), was shown to have efficacy superior to all-trans retinoic acid as a chemopreventive agent in the N-nitroso-N-methylurea-induced rat mammary carcinoma model. To further explore the specific contribution RXR activation may play in suppression of carcinogenesis, the efficacy of LGD1069 (Targretin), an RXR-selective ligand, in the N-nitroso-N-methylurea-induced rat mammary tumor model was studied. LGD1069-treated animals showed a 90% reduction in tumor burden and tumor incidence compared with vehicle-treated rats with an efficacy similar to that achieved with tamoxifen. LGD1069 was very well tolerated during 13 weeks of chronic therapy with no classic signs of "retinoid-associated" toxicities. These data demonstrate that LGD1069, an RXR-selective ligand, can act as a highly effective and benign chemopreventive agent for mammary carcinoma.

To: Robert Cohen who wrote (15815)	2/25/1998 10:20:00 AM
From: David L. Hachey	Respond to of 32384

Robert, Henry pointed this out to me a few posts back. I still feel the topic needs more publicity. Although targretin has a remarkably safe treatment profile, I would be concerned about teratogenic effects when used in the general population. I'm sure LGND has looked at this issue, it's a normal part of the toxicology screening phase especially considering the teratogenicity and fetotoxicity of tretinoin. Has anyone published on this issue with regard to targretin? ...Dave